International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia

2003 ◽  
Vol 11 (6) ◽  
pp. 638-647 ◽  
Author(s):  
Dilip V. Jeste ◽  
Yoram Barak ◽  
Subramoniam Madhusoodanan ◽  
Fred Grossman ◽  
Georges Gharabawi
Keyword(s):  
Elderly Patients ◽  
Atypical Antipsychotics ◽  
Chronic Schizophrenia ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial

A Double-blind Trial of Oxypertine for Anxiety Neurosis

1965 ◽  
Vol 111 (475) ◽  
pp. 527-529 ◽  
Author(s):  
J. T. Robinson ◽  
L. S. Davies ◽  
Norman Kreitman ◽  
J. B. Knowles
Keyword(s):  
Clinical Trial ◽  
Chronic Schizophrenia ◽  
Anxiety Symptoms ◽  
Anxiety Scale ◽  
Adjunctive Treatment ◽  
Double Blind Trial ◽  
Anxiety Neurosis ◽  
Double Blind ◽  
Blind Trial ◽  
Chronic Anxiety

Oxypertine is a new piperazine derivative, believed to have tranquillizing, antiadrenergic and hypotensive properties. Unpublished reports have suggested that it might be useful in chronic schizophrenia, although the recent study by Calwell et al. (1964) shows that its usefulness in this condition is limited. In view of its putative tranquillizing effect, the present clinical trial was undertaken to determine, under double-blind conditions, its efficacy as an adjunctive treatment for chronic anxiety neurosis. Ratings of anxiety symptoms were the major criteria for assessing the patients' progress, but the IPAT Anxiety Scale (Cattell and Scheier, 1957) was also included as a potentially useful measure of anxiety. An investigation of its validity was a subsidiary aim of the study.

A Double-Blind Trial: Vivalan against Placebo in Depressed Elderly Patients

1980 ◽  
Vol 8 (1) ◽  
pp. 18-21 ◽  
Author(s):  
L Knorring Von
Keyword(s):  
Elderly Patients ◽  
Cardiac Disease ◽  
Depressive Illness ◽  
Primary Diagnosis ◽  
Controlled Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Depressed Patients ◽  
Depression Ratings

A double-blind controlled study of viloxazine against placebo in elderly depressed patients with a primary diagnosis of depressive illness records statistically significant improvements in depression ratings in the viloxazine group after three weeks. Viloxazine was effective and well tolerated at doses of 100 to 200 mg in depressed elderly patients, several of whom had concurrent cardiac disease.

A Comparative Trial of Haloperidol and Thioridazine: Management of Chronic Schizophrenia

1973 ◽  
Vol 7 (1) ◽  
pp. 52-57 ◽  
Author(s):  
M. J. Weston ◽  
R. Bentley ◽  
A. Unwin ◽  
M. Morris ◽  
M. A. Harper
Keyword(s):  
Comparative Trial ◽  
Chronic Schizophrenia ◽  
The Other ◽  
Clinical Population ◽  
Therapeutic Effects ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Chronic Schizophrenic ◽  
Compare And Contrast

A double-blind trial was conducted which attempted to compare and contrast the therapeutic effects of haloperidol and thioridazine in a chronic schizophrenic population. The psychiatric use of these two drugs, one a butyrophenone, the other a phenothiazine, is discussed with reference to the management of this clinical population.

scholarly journals Effects of Ketamine-Propofol Mixture on Intraocular Pressure and Hemodynamic in Elderly Patients: A Randomized Double-Blind Trial

2014 ◽  
Vol 42 (1) ◽  
pp. 12-18 ◽  
Author(s):  
Mustafa Said Aydogan ◽  
Soner Demirel ◽  
Mehmet Ali Erdogan ◽  
Penpegul Firat ◽  
Cemil Colak ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Elderly Patients ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial

A Comparative Double Blind Trial of Pimozide and Fluphenazine in Chronic Schizophrenia

1970 ◽  
Vol 117 (541) ◽  
pp. 683-684 ◽  
Author(s):  
P. A. Morris ◽  
D. H. MacKenzie ◽  
H. C. Masheter
Keyword(s):  
Oral Administration ◽  
Chronic Schizophrenia ◽  
Peak Effect ◽  
Neuroleptic Drug ◽  
Double Blind Trial ◽  
Double Blind ◽  
Duration Of Action ◽  
Blind Trial

Pimozide is a new neuroleptic drug and is chemically described as bis-para-fluoro-phenyl-butylpiperidine. It is active after oral administration, with a 24 hour duration of action and a peak effect lasting four to six hours (1). Superiority over placebo has been demonstrated by Brugmans (2).

Sign in / Sign up

Export Citation Format

Share Document